Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia

We previously reported on children with opsoclonus-ataxia and found pervasive neurodevelopmental deficits, years after onset, without a clear relationship to treatment modality or timing of treatment. A significant negative correlation of functional status with age at testing raised a question of wh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics (Evanston) 2005-10, Vol.116 (4), p.901-907
Hauptverfasser: Mitchell, Wendy G, Brumm, Virdette L, Azen, Colleen G, Patterson, Kirsten E, Aller, Sonia K, Rodriguez, Jenny
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 907
container_issue 4
container_start_page 901
container_title Pediatrics (Evanston)
container_volume 116
creator Mitchell, Wendy G
Brumm, Virdette L
Azen, Colleen G
Patterson, Kirsten E
Aller, Sonia K
Rodriguez, Jenny
description We previously reported on children with opsoclonus-ataxia and found pervasive neurodevelopmental deficits, years after onset, without a clear relationship to treatment modality or timing of treatment. A significant negative correlation of functional status with age at testing raised a question of whether opsoclonus-ataxia is a progressive encephalopathy. We attempted to answer this question with serial testing. In addition, we examined the relationship between clinical course and developmental outcome. Thirteen of 17 children with opsoclonus-ataxia, all with neuroblastoma, who were previously reported were reevaluated a second time 2 to 4 years after the initial assessment. One subject who lived out of state was partially reevaluated and is included. Five new subjects (2 with neuroblastoma and 3 without) were also enrolled. Each was evaluated twice at a minimum interval of 1 year between sessions. Intercurrent medical course was recorded, emphasizing medication and relapse history. Cognitive, adaptive behavior, academic, speech and language, and motor abilities were assessed. For the group as a whole, overall standardized, age-adjusted cognitive scores improved. Generally, younger subjects' cognitive and adaptive behavior scores improved more than older subjects. Although all subjects had gains in speech, language, and motor function, some progressed at a slow pace, and in some instances, standard scores dropped. There was a striking influence of clinical course. Although initial presentation was severe and all subjects required high doses of corticosteroids or corticotropin, 5 had a monophasic course and were able to be weaned from treatment without relapses. Fourteen had multiple relapses over the years, generally with reduction of medication or intercurrent illnesses. Of the 5 children with monophasic course, 4 are currently functioning in the average range with a full-scale IQ of > or =90 and age-appropriate academic and adaptive skills. The results continue to raise concern that opsoclonus-ataxia is sometimes a progressive encephalopathy. A minority of children with opsoclonus-ataxia have a monophasic course. Despite initial severity of symptoms, these children may have a more benign prognosis. For the majority of children with opsoclonus-ataxia, the course includes multiple relapses and requires prolonged treatment. Developmental sequelae are significant in these children with chronic course.
doi_str_mv 10.1542/peds.2004-2377
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68649931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A137965672</galeid><sourcerecordid>A137965672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-468d3f81331d968579c5d3820463f26e43cfadf85c0075fe7948ed8c479c33993</originalsourceid><addsrcrecordid>eNqF0s-LEzEUB_BBFLeuXj1KERQ8TM2vyY9jKesqVHtRPIaYeZlmSSc1yazrf2_KFupKQXJICJ-XFx7fpnmJ0QJ3jLzfQ58XBCHWEirEo2aGkZItI6J73MwQorhlCHUXzbOcb1BlnSBPmwvMsVJcqVnzeR3HwZep96MJ8y8wpdjDLYS438FY6tXVrQmTKT6O8-jmq60PfYJx_t2X7Xyzz9GGOE65XRZz583z5okzIcOL437ZfPtw9XX1sV1vrj-tluvWdlyVlnHZUycxpbhXXHZC2a6nkiDGqSMcGLXO9E52FiHRORCKSeilZRVSqhS9bN7ev7tP8ecEueidzxZCMCPEKWsuOasM_xdixbDgnFf4-h94E6dUZ5I1IZJIxTtRUXuPBhNA-9HFkowdYIRk6hjA-Xq9xFRUzQWpfnHG19XDztuzBe8eFFRT4K4MZspZy-v1Q9ueszaGAAPoOu_V5uxnbIo5J3B6n_zOpN8aI33Ikj5kSR-ypA9ZqgWvjiOZfuygP_FjeCp4cwQmWxNcMqP1-eQE5h1m-NR564ftL5_g0MmbkrzNfx0x5ppphTD9A6Qt3rc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228289657</pqid></control><display><type>article</type><title>Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Mitchell, Wendy G ; Brumm, Virdette L ; Azen, Colleen G ; Patterson, Kirsten E ; Aller, Sonia K ; Rodriguez, Jenny</creator><creatorcontrib>Mitchell, Wendy G ; Brumm, Virdette L ; Azen, Colleen G ; Patterson, Kirsten E ; Aller, Sonia K ; Rodriguez, Jenny</creatorcontrib><description>We previously reported on children with opsoclonus-ataxia and found pervasive neurodevelopmental deficits, years after onset, without a clear relationship to treatment modality or timing of treatment. A significant negative correlation of functional status with age at testing raised a question of whether opsoclonus-ataxia is a progressive encephalopathy. We attempted to answer this question with serial testing. In addition, we examined the relationship between clinical course and developmental outcome. Thirteen of 17 children with opsoclonus-ataxia, all with neuroblastoma, who were previously reported were reevaluated a second time 2 to 4 years after the initial assessment. One subject who lived out of state was partially reevaluated and is included. Five new subjects (2 with neuroblastoma and 3 without) were also enrolled. Each was evaluated twice at a minimum interval of 1 year between sessions. Intercurrent medical course was recorded, emphasizing medication and relapse history. Cognitive, adaptive behavior, academic, speech and language, and motor abilities were assessed. For the group as a whole, overall standardized, age-adjusted cognitive scores improved. Generally, younger subjects' cognitive and adaptive behavior scores improved more than older subjects. Although all subjects had gains in speech, language, and motor function, some progressed at a slow pace, and in some instances, standard scores dropped. There was a striking influence of clinical course. Although initial presentation was severe and all subjects required high doses of corticosteroids or corticotropin, 5 had a monophasic course and were able to be weaned from treatment without relapses. Fourteen had multiple relapses over the years, generally with reduction of medication or intercurrent illnesses. Of the 5 children with monophasic course, 4 are currently functioning in the average range with a full-scale IQ of &gt; or =90 and age-appropriate academic and adaptive skills. The results continue to raise concern that opsoclonus-ataxia is sometimes a progressive encephalopathy. A minority of children with opsoclonus-ataxia have a monophasic course. Despite initial severity of symptoms, these children may have a more benign prognosis. For the majority of children with opsoclonus-ataxia, the course includes multiple relapses and requires prolonged treatment. Developmental sequelae are significant in these children with chronic course.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2004-2377</identifier><identifier>PMID: 16199699</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: Am Acad Pediatrics</publisher><subject>Ataxia ; Ataxia - complications ; Ataxia - drug therapy ; Biological and medical sciences ; Child ; Child Behavior ; Child Development ; Child, Preschool ; Children &amp; youth ; Clinical outcomes ; Developmental Disabilities - diagnosis ; Developmental Disabilities - etiology ; Diseases ; Female ; General aspects ; Humans ; Infant ; Infants ; Male ; Medical sciences ; Medical treatment ; Movement disorders ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neuroblastoma - complications ; Neurological disorders ; Neurology ; Ocular Motility Disorders - complications ; Ocular Motility Disorders - drug therapy ; Oculomotor disorders ; Ophthalmology ; Paraneoplastic Syndromes, Nervous System - complications ; Paraneoplastic Syndromes, Nervous System - drug therapy ; Pediatrics ; Psychomotor Performance ; Recurrence ; Toddlers</subject><ispartof>Pediatrics (Evanston), 2005-10, Vol.116 (4), p.901-907</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 American Academy of Pediatrics</rights><rights>Copyright American Academy of Pediatrics Oct 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-468d3f81331d968579c5d3820463f26e43cfadf85c0075fe7948ed8c479c33993</citedby><cites>FETCH-LOGICAL-c569t-468d3f81331d968579c5d3820463f26e43cfadf85c0075fe7948ed8c479c33993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17165141$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16199699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mitchell, Wendy G</creatorcontrib><creatorcontrib>Brumm, Virdette L</creatorcontrib><creatorcontrib>Azen, Colleen G</creatorcontrib><creatorcontrib>Patterson, Kirsten E</creatorcontrib><creatorcontrib>Aller, Sonia K</creatorcontrib><creatorcontrib>Rodriguez, Jenny</creatorcontrib><title>Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>We previously reported on children with opsoclonus-ataxia and found pervasive neurodevelopmental deficits, years after onset, without a clear relationship to treatment modality or timing of treatment. A significant negative correlation of functional status with age at testing raised a question of whether opsoclonus-ataxia is a progressive encephalopathy. We attempted to answer this question with serial testing. In addition, we examined the relationship between clinical course and developmental outcome. Thirteen of 17 children with opsoclonus-ataxia, all with neuroblastoma, who were previously reported were reevaluated a second time 2 to 4 years after the initial assessment. One subject who lived out of state was partially reevaluated and is included. Five new subjects (2 with neuroblastoma and 3 without) were also enrolled. Each was evaluated twice at a minimum interval of 1 year between sessions. Intercurrent medical course was recorded, emphasizing medication and relapse history. Cognitive, adaptive behavior, academic, speech and language, and motor abilities were assessed. For the group as a whole, overall standardized, age-adjusted cognitive scores improved. Generally, younger subjects' cognitive and adaptive behavior scores improved more than older subjects. Although all subjects had gains in speech, language, and motor function, some progressed at a slow pace, and in some instances, standard scores dropped. There was a striking influence of clinical course. Although initial presentation was severe and all subjects required high doses of corticosteroids or corticotropin, 5 had a monophasic course and were able to be weaned from treatment without relapses. Fourteen had multiple relapses over the years, generally with reduction of medication or intercurrent illnesses. Of the 5 children with monophasic course, 4 are currently functioning in the average range with a full-scale IQ of &gt; or =90 and age-appropriate academic and adaptive skills. The results continue to raise concern that opsoclonus-ataxia is sometimes a progressive encephalopathy. A minority of children with opsoclonus-ataxia have a monophasic course. Despite initial severity of symptoms, these children may have a more benign prognosis. For the majority of children with opsoclonus-ataxia, the course includes multiple relapses and requires prolonged treatment. Developmental sequelae are significant in these children with chronic course.</description><subject>Ataxia</subject><subject>Ataxia - complications</subject><subject>Ataxia - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child Behavior</subject><subject>Child Development</subject><subject>Child, Preschool</subject><subject>Children &amp; youth</subject><subject>Clinical outcomes</subject><subject>Developmental Disabilities - diagnosis</subject><subject>Developmental Disabilities - etiology</subject><subject>Diseases</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infant</subject><subject>Infants</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Movement disorders</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neuroblastoma - complications</subject><subject>Neurological disorders</subject><subject>Neurology</subject><subject>Ocular Motility Disorders - complications</subject><subject>Ocular Motility Disorders - drug therapy</subject><subject>Oculomotor disorders</subject><subject>Ophthalmology</subject><subject>Paraneoplastic Syndromes, Nervous System - complications</subject><subject>Paraneoplastic Syndromes, Nervous System - drug therapy</subject><subject>Pediatrics</subject><subject>Psychomotor Performance</subject><subject>Recurrence</subject><subject>Toddlers</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0s-LEzEUB_BBFLeuXj1KERQ8TM2vyY9jKesqVHtRPIaYeZlmSSc1yazrf2_KFupKQXJICJ-XFx7fpnmJ0QJ3jLzfQ58XBCHWEirEo2aGkZItI6J73MwQorhlCHUXzbOcb1BlnSBPmwvMsVJcqVnzeR3HwZep96MJ8y8wpdjDLYS438FY6tXVrQmTKT6O8-jmq60PfYJx_t2X7Xyzz9GGOE65XRZz583z5okzIcOL437ZfPtw9XX1sV1vrj-tluvWdlyVlnHZUycxpbhXXHZC2a6nkiDGqSMcGLXO9E52FiHRORCKSeilZRVSqhS9bN7ev7tP8ecEueidzxZCMCPEKWsuOasM_xdixbDgnFf4-h94E6dUZ5I1IZJIxTtRUXuPBhNA-9HFkowdYIRk6hjA-Xq9xFRUzQWpfnHG19XDztuzBe8eFFRT4K4MZspZy-v1Q9ueszaGAAPoOu_V5uxnbIo5J3B6n_zOpN8aI33Ikj5kSR-ypA9ZqgWvjiOZfuygP_FjeCp4cwQmWxNcMqP1-eQE5h1m-NR564ftL5_g0MmbkrzNfx0x5ppphTD9A6Qt3rc</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Mitchell, Wendy G</creator><creator>Brumm, Virdette L</creator><creator>Azen, Colleen G</creator><creator>Patterson, Kirsten E</creator><creator>Aller, Sonia K</creator><creator>Rodriguez, Jenny</creator><general>Am Acad Pediatrics</general><general>American Academy of Pediatrics</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia</title><author>Mitchell, Wendy G ; Brumm, Virdette L ; Azen, Colleen G ; Patterson, Kirsten E ; Aller, Sonia K ; Rodriguez, Jenny</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-468d3f81331d968579c5d3820463f26e43cfadf85c0075fe7948ed8c479c33993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Ataxia</topic><topic>Ataxia - complications</topic><topic>Ataxia - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child Behavior</topic><topic>Child Development</topic><topic>Child, Preschool</topic><topic>Children &amp; youth</topic><topic>Clinical outcomes</topic><topic>Developmental Disabilities - diagnosis</topic><topic>Developmental Disabilities - etiology</topic><topic>Diseases</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infant</topic><topic>Infants</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Movement disorders</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neuroblastoma - complications</topic><topic>Neurological disorders</topic><topic>Neurology</topic><topic>Ocular Motility Disorders - complications</topic><topic>Ocular Motility Disorders - drug therapy</topic><topic>Oculomotor disorders</topic><topic>Ophthalmology</topic><topic>Paraneoplastic Syndromes, Nervous System - complications</topic><topic>Paraneoplastic Syndromes, Nervous System - drug therapy</topic><topic>Pediatrics</topic><topic>Psychomotor Performance</topic><topic>Recurrence</topic><topic>Toddlers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitchell, Wendy G</creatorcontrib><creatorcontrib>Brumm, Virdette L</creatorcontrib><creatorcontrib>Azen, Colleen G</creatorcontrib><creatorcontrib>Patterson, Kirsten E</creatorcontrib><creatorcontrib>Aller, Sonia K</creatorcontrib><creatorcontrib>Rodriguez, Jenny</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitchell, Wendy G</au><au>Brumm, Virdette L</au><au>Azen, Colleen G</au><au>Patterson, Kirsten E</au><au>Aller, Sonia K</au><au>Rodriguez, Jenny</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>116</volume><issue>4</issue><spage>901</spage><epage>907</epage><pages>901-907</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>We previously reported on children with opsoclonus-ataxia and found pervasive neurodevelopmental deficits, years after onset, without a clear relationship to treatment modality or timing of treatment. A significant negative correlation of functional status with age at testing raised a question of whether opsoclonus-ataxia is a progressive encephalopathy. We attempted to answer this question with serial testing. In addition, we examined the relationship between clinical course and developmental outcome. Thirteen of 17 children with opsoclonus-ataxia, all with neuroblastoma, who were previously reported were reevaluated a second time 2 to 4 years after the initial assessment. One subject who lived out of state was partially reevaluated and is included. Five new subjects (2 with neuroblastoma and 3 without) were also enrolled. Each was evaluated twice at a minimum interval of 1 year between sessions. Intercurrent medical course was recorded, emphasizing medication and relapse history. Cognitive, adaptive behavior, academic, speech and language, and motor abilities were assessed. For the group as a whole, overall standardized, age-adjusted cognitive scores improved. Generally, younger subjects' cognitive and adaptive behavior scores improved more than older subjects. Although all subjects had gains in speech, language, and motor function, some progressed at a slow pace, and in some instances, standard scores dropped. There was a striking influence of clinical course. Although initial presentation was severe and all subjects required high doses of corticosteroids or corticotropin, 5 had a monophasic course and were able to be weaned from treatment without relapses. Fourteen had multiple relapses over the years, generally with reduction of medication or intercurrent illnesses. Of the 5 children with monophasic course, 4 are currently functioning in the average range with a full-scale IQ of &gt; or =90 and age-appropriate academic and adaptive skills. The results continue to raise concern that opsoclonus-ataxia is sometimes a progressive encephalopathy. A minority of children with opsoclonus-ataxia have a monophasic course. Despite initial severity of symptoms, these children may have a more benign prognosis. For the majority of children with opsoclonus-ataxia, the course includes multiple relapses and requires prolonged treatment. Developmental sequelae are significant in these children with chronic course.</abstract><cop>Elk Grove Village, IL</cop><pub>Am Acad Pediatrics</pub><pmid>16199699</pmid><doi>10.1542/peds.2004-2377</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 2005-10, Vol.116 (4), p.901-907
issn 0031-4005
1098-4275
language eng
recordid cdi_proquest_miscellaneous_68649931
source MEDLINE; EZB Electronic Journals Library
subjects Ataxia
Ataxia - complications
Ataxia - drug therapy
Biological and medical sciences
Child
Child Behavior
Child Development
Child, Preschool
Children & youth
Clinical outcomes
Developmental Disabilities - diagnosis
Developmental Disabilities - etiology
Diseases
Female
General aspects
Humans
Infant
Infants
Male
Medical sciences
Medical treatment
Movement disorders
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neuroblastoma - complications
Neurological disorders
Neurology
Ocular Motility Disorders - complications
Ocular Motility Disorders - drug therapy
Oculomotor disorders
Ophthalmology
Paraneoplastic Syndromes, Nervous System - complications
Paraneoplastic Syndromes, Nervous System - drug therapy
Pediatrics
Psychomotor Performance
Recurrence
Toddlers
title Longitudinal Neurodevelopmental Evaluation of Children With Opsoclonus-Ataxia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A52%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20Neurodevelopmental%20Evaluation%20of%20Children%20With%20Opsoclonus-Ataxia&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Mitchell,%20Wendy%20G&rft.date=2005-10-01&rft.volume=116&rft.issue=4&rft.spage=901&rft.epage=907&rft.pages=901-907&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2004-2377&rft_dat=%3Cgale_proqu%3EA137965672%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=228289657&rft_id=info:pmid/16199699&rft_galeid=A137965672&rfr_iscdi=true